Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 508 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Ellen Gifts 25K To Army Veteran Who Fought Breast Cancer And... November 18, 2019 Trastuzumab Deruxtecan Leads to Longer PFS and OS Compared with Chemotherapy... July 14, 2022 The Doctor Will See You Now…On the Screen July 2, 2020 Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with... December 6, 2024 Load more HOT NEWS Fructose Fuels Cancer Growth Indirectly, Lab Study Finds Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre... EMA Recommends Extension of Indications for Nivolumab When Ellen Found Out There Was A Grieving Mother In The...
